News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,386 Results
Type
Article (43822)
Company Profile (318)
Press Release (698232)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210994)
Career Advice (2109)
Deals (36759)
Drug Delivery (124)
Drug Development (83421)
Employer Resources (176)
FDA (16831)
Job Trends (15505)
News (357380)
Policy (34132)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2616)
Accelerated approval (34)
Adcomms (26)
Allergies (150)
Alliances (51584)
ALS (174)
Alzheimer's disease (1699)
Antibody-drug conjugate (ADC) (327)
Approvals (17096)
Artificial intelligence (543)
Autoimmune disease (162)
Automation (42)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (198)
Biotechnology (188)
Bladder cancer (160)
Brain cancer (61)
Breast cancer (655)
Cancer (4935)
Cardiovascular disease (421)
Career advice (1788)
Career pathing (37)
CAR-T (287)
CDC (49)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (71210)
Collaboration (1776)
Company closure (4)
Compensation (1181)
Complete response letters (65)
COVID-19 (2788)
CRISPR (99)
C-suite (890)
Cystic fibrosis (148)
Data (6337)
Decentralized trials (2)
Denatured (36)
Depression (138)
Diabetes (510)
Diagnostics (6797)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (263)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (235)
Earnings (91993)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120363)
Executive appointments (1008)
FDA (20014)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1498)
Gene editing (206)
Generative AI (46)
Gene therapy (617)
GLP-1 (1015)
Government (4810)
Grass and pollen (7)
Guidances (385)
Healthcare (19066)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (61)
Indications (119)
Infectious disease (3065)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (259)
Interviews (327)
IPO (16921)
IRA (57)
Job creations (4072)
Job search strategy (1498)
JPM (64)
Kidney cancer (16)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8425)
Liver cancer (92)
Longevity (16)
Lung cancer (665)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (837)
MASH (170)
Medical device (13865)
Medtech (13921)
Mergers & acquisitions (20914)
Metabolic disorders (1311)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (328)
Neuropsychiatric disorders (92)
Neuroscience (2973)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4563)
Now hiring (68)
Obesity (620)
Opinion (289)
Ovarian cancer (168)
Pain (217)
Pancreatic cancer (232)
Parkinson's disease (286)
Partnered (34)
Patents (515)
Patient recruitment (502)
Peanut (60)
People (60952)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22103)
Phase 2 (31308)
Phase 3 (23460)
Pipeline (5491)
Policy (303)
Postmarket research (2655)
Preclinical (9390)
Press Release (68)
Prostate cancer (242)
Psychedelics (50)
Radiopharmaceuticals (290)
Rare diseases (880)
Real estate (6306)
Recruiting (72)
Regulatory (25453)
Reports (53)
Research institute (2441)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (156)
Series A (246)
Series B (194)
Service/supplier (11)
Sickle cell disease (100)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3766)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (78)
Vaccines (1043)
Venture capital (91)
Weight loss (405)
Women's health (94)
Worklife (18)
Date
Today (143)
Last 7 days (576)
Last 30 days (2370)
Last 365 days (30303)
2026 (4046)
2025 (30679)
2024 (35767)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38617)
2014 (32517)
2013 (27630)
2012 (29731)
2011 (30487)
2010 (28497)
Location
Africa (801)
Alabama (84)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (42172)
Australia (6754)
California (11465)
Canada (3342)
China (1143)
Colorado (483)
Connecticut (486)
Delaware (345)
Europe (90449)
Florida (1717)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (889)
India (72)
Indiana (537)
Iowa (22)
Japan (448)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1404)
Massachusetts (8249)
Michigan (330)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (79)
New Jersey (3046)
New Mexico (29)
New York (3026)
North Carolina (1492)
North Dakota (8)
Northern California (5600)
Ohio (339)
Oklahoma (22)
Oregon (46)
Pennsylvania (2322)
Puerto Rico (24)
Rhode Island (48)
South America (1176)
South Carolina (68)
South Dakota (1)
Southern California (4468)
Tennessee (177)
Texas (1770)
United States (40761)
Utah (343)
Vermont (1)
Virginia (280)
Washington D.C. (81)
Washington State (937)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,386 Results for "merrimack pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. announced that the stockholders at a Special Meeting held overwhelmingly approved adopting a Plan of Dissolution.
May 10, 2024
·
6 min read
Deals
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024.
May 9, 2024
·
9 min read
Genetown
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. announced that it has filed notice with NASDAQ of the Company’s intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024.
April 30, 2024
·
10 min read
Genetown
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its full year 2023 financial results for the period ended December 31, 2023.
March 7, 2024
·
7 min read
Genetown
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
March 27, 2024
·
9 min read
Business
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its third quarter 2023 financial results for the period ended September 30, 2023.
November 2, 2023
·
6 min read
Press Releases
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
·
12 min read
Press Releases
Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
February 8, 2026
·
7 min read
Business
Merrimack Reports Second Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its second quarter 2023 financial results for the period ended June 30, 2023.
August 3, 2023
·
9 min read
Press Releases
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 16, 2026
·
6 min read
1 of 74,239
Next
